Erhan Berrak, MD [clinicaltrials_resource:15526b4e6b7d64dd469e7b0e3b0b6333]
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer [clinicaltrials:NCT01328249]Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer [clinicaltrials:NCT02481050]clinicaltrials:NCT02513472
overall official [clinicaltrials_vocabulary:overall-official]
Erhan Berrak, MD [clinicaltrials_resource:15526b4e6b7d64dd469e7b0e3b0b6333]
Bio2RDF identifier
15526b4e6b7d64dd469e7b0e3b0b6333
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:15526b4e6b7d64dd469e7b0e3b0b6333
affiliation [clinicaltrials_vocabulary:affiliation]
email [clinicaltrials_vocabulary:email]
ana_almonte@eisai.com
charles_kwak@eisai.com
last name [clinicaltrials_vocabulary:last-name]
Erhan Berrak, MD
phone [clinicaltrials_vocabulary:phone]
201-746-2428
201-746-2612
role [clinicaltrials_vocabulary:role]
Study Director
identifier
clinicaltrials_resource:15526b4e6b7d64dd469e7b0e3b0b6333
title
Erhan Berrak, MD
@en
type
label
Erhan Berrak, MD [clinicaltrials_resource:15526b4e6b7d64dd469e7b0e3b0b6333]
@en